2025-04-09 - Analysis Report
## Merck & Co Inc (MRK) Stock Report

**0. Key Figures Summary:**

* **Cumulative Return (MRK):** 8.64%
* **Cumulative Return (VOO/S&P 500):** 55.60%
* **Return Difference:** -46.96%
* **Relative Divergence:** 32.2% (Indicates MRK's performance is relatively lower than VOO, but within the historical range)


**1. Company Overview and Performance Comparison:**

Merck & Co Inc is a leading global healthcare company specializing in the discovery, development, and manufacturing of prescription pharmaceuticals, vaccines, and animal health products.  The provided data shows that MRK significantly underperformed the S&P 500 (VOO) over the analyzed period, lagging by approximately 47 percentage points.  The relative divergence of 32.2% indicates that this underperformance is within the historical range of its relative performance to VOO, though on the lower end.

**Alpha and Beta Analysis:**

The provided data reveals fluctuating alpha and beta values over the years.  While alpha values suggest periods of outperformance (positive alpha), this has not been consistent. Beta values generally hover around 1, meaning the stock's price volatility correlates well with the market, though there were periods of higher beta which implies greater volatility than the market.  The consistent high Maximum Drawdown (MDD) values indicate the stock's susceptibility to significant price drops.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 5.0% | 58.4% | -24.0% | 0.0 | 109.0 |
| 2016-2018  | 42.0% | 66.6% | 24.0% | 0.1 | 152.6 |
| 2017-2019  | 40.0% | 66.6% | 11.0% | 0.2 | 186.6 |
| 2018-2020  | 19.0% | 66.6% | -6.0% | 0.4 | 173.1 |
| 2019-2021  | -1.0% | 65.6% | -55.0% | 0.5 | 176.2 |
| 2020-2022  | 13.0% | 69.3% | 7.0% | 0.5 | 263.2 |
| 2021-2023  | 35.0% | 69.3% | 19.0% | 0.3 | 265.9 |
| 2022-2024  | -6.0% | 69.3% | -23.0% | 0.3 | 249.2 |
| 2023-2025  | -44.0% | 70.3% | -48.0% | 0.1 | 201.2 |


**2. Recent Price Movement:**

* **Closing Price:** $79.595
* **Last Market Price:** $79.635
* **Previous Close:** $81.18
* **Daily Change:** -$1.545 (a decrease of ~1.9%)
* **5-Day Moving Average:** $84.235
* **20-Day Moving Average:** $90.078
* **60-Day Moving Average:** $91.486

The stock price is currently trading below its 5, 20, and 60-day moving averages, suggesting a downtrend.


**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4883 (High Risk)
* **RSI:** 14.57 (Oversold territory; often signals a potential bounce but not guaranteed)
* **PPO:** -1.35 (Negative value indicates bearish momentum)
* **Recent Relative Divergence:** +13.1 (Short-term upward trend)
* **Expected Return (2+ years):** -20.2% (Significant underperformance relative to the S&P 500 is anticipated over the long term based on current trends).

The significant price drop in the last market closing price (-1.9%) points towards a bearish trend and should be considered.  The high MRI, low RSI, and negative PPO value further support this bearish outlook.  However, the recent positive relative divergence suggests a potential short-term upward correction.


**4. Recent Earnings Analysis:**

The earnings data shows some volatility in EPS and relatively stable revenue.  There's no clear upward or downward trend visible in this short timeframe.  Further analysis with a longer time horizon is needed to identify clear trends.

| Date       | EPS  | Revenue       |
|------------|------|----------------|
| 2024-11-06 | 1.25 | $16.66 B       |
| 2024-08-05 | 2.15 | $16.11 B       |
| 2024-05-03 | 1.88 | $15.78 B       |
| 2023-11-03 | 1.87 | $15.96 B       |
| 2024-11-06 | 1.87 | $15.96 B       |


**5. Financial Information:**

Revenue has remained relatively stable over the last year, with a slight increase. Profit margins are high and consistent, showcasing strong profitability.  Equity and ROE show some variability, possibly due to fluctuating profits and/or share buybacks.  Further investigation into the company's financial statements is recommended.


| Quarter     | Revenue    | Profit Margin |
|-------------|------------|---------------|
| 2024-12-31 | $15.62B    | 75.50%        |
| 2024-09-30 | $16.66B    | 75.51%        |
| 2024-06-30 | $16.11B    | 76.76%        |
| 2024-03-31 | $15.78B    | 77.56%        |
| 2023-12-31 | $14.63B    | 73.26%        |

| Quarter     | Equity      | ROE    |
|-------------|-------------|--------|
| 2024-12-31 | $46.31B     | 8.08%  |
| 2024-09-30 | $44.50B     | 7.09%  |
| 2024-06-30 | $43.58B     | 12.52% |
| 2024-03-31 | $40.36B     | 11.80% |
| 2023-12-31 | $37.58B     | -3.26% |


**6. Overall Analysis:**

Merck & Co Inc (MRK) currently exhibits a bearish outlook.  The stock significantly underperformed the S&P 500 over the analyzed period and technical indicators point towards a bearish trend.  While the company demonstrates strong profitability and stable revenue, the negative expected return relative to the S&P 500 suggests caution for long-term investors.  Further detailed fundamental analysis is crucial to evaluate potential investment opportunities.  The high MDD consistently observed in the CAGR analysis should be a primary concern for investors.  The recent negative price movement further reinforces the need for cautious evaluation.  Investors should consider the substantial risk implied by the high market risk indicator and the negative expected return before making any investment decisions.
